Pfizer/Spark team gets a ‘breakthrough’ in gene therapy alliance
A couple of years ago, Pfizer set up a new group to tackle the hot gene therapy field, drafting Michael Linden from King’s College to get it going. Right off the bat, the pharma giant also teamed with Spark Therapeutics – a hot player in the gene therapy field – to partner on an experimental program for hemophilia B. And now the partners can boast of a ‘breakthrough’ drug designation at the FDA to help speed their work along.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.